EIGR's Business Model
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
| Sector & Industry | Healthcare / Biotechnology |
| Website | https://www.eigerbio.com |
| CEO (Chief Executive Officer) | David Apelian |
| Number of Employees | |
| IPO date | January 30, 2014 |
EIGR Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | US |
| Address | 2155 Park Boulevard |
| City | Palo Alto |
| State | CA |
| Phone | 650 272 6138 |
| Zip Code | 94306 |
| Other Identifiers | |
| CIK | 0001305253 |
| ISIN | US28249U2042 |
| CUSIP | 28249U105 |
| Open | 1.9 |
| Previous Close | 1.725 |
| Volume | 136.3 Thou. |
| Average Volume | 131.9 Thou. |
| Day’s Range | 1.725 – 1.9 |
| 52 Week Range | 1.725-1.9 |
| MA (50) | 1.73 |
| MA (200) | 1.73 |
| Market Cap | 2.55 Mil. |
| Shares Out. | 1.48 Mil. |
| Earnings Date | Apr 07, 2025 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
